Related Experiment Video
Updated: Jan 7, 2026

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
Xin-Fu-Kang oral liquid improves cardiac function and attenuates miR-223-associated NF-κB/NLRP3 pyroptotic signaling
Zelin Ye1, Mingrui Liu2, Xiaohan Zhang1
1Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Insights
Xin-Fu-Kang (XFK) protects against chronic heart failure (CHF) by modulating pyroptotic signaling. This traditional Chinese medicine formula upregulates miR-223, which inhibits NF-κB and NLRP3 inflammasome activation, reducing inflammation and improving cardiac function.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Inflammation Research
Background:
- Pyroptotic signaling, involving nuclear factor-kappa B (NF-κB) and NOD-like receptor family pyrin domain-containing 3 (NLRP3), is implicated in chronic heart failure (CHF).
- Xin-Fu-Kang (XFK), a traditional Chinese nine-herb formula, is clinically used for CHF characterized by "qi deficiency and blood stasis."
- The precise mechanism by which XFK modulates myocardial pyroptotic signaling, particularly via miR-223 regulation of NF-κB, remains unclear.
Purpose of the Study:
- To investigate whether Xin-Fu-Kang (XFK) modulates myocardial pyroptotic signaling in chronic heart failure (CHF).
- To determine the role of miR-223 in mediating the effects of XFK on NF-κB and NLRP3 inflammasome activation in CHF.
- To elucidate the potential of XFK as an adjunctive therapy for inflammation-driven cardiac dysfunction.
Main Methods:
- Established a rat model of CHF via coronary artery ligation and an in vitro oxygen-glucose deprivation/reoxygenation (OGD/R) model in H9c2 cardiomyocytes.
- Assessed cardiac function, structure, inflammation (IL-1β, IL-18), and pyroptotic markers (NLRP3, caspase-1, ASC, GSDMD-N, NF-κB p65 phosphorylation/translocation).
- Utilized miR-223 gain- and loss-of-function studies, including inhibitor rescue experiments, to establish causality.
Main Results:
- XFK treatment improved cardiac function and structure, reduced myocardial inflammation, fibrosis, and cardiomyocyte apoptosis in the CHF model.
- XFK attenuated OGD/R-induced injury in cardiomyocytes by suppressing NLRP3 inflammasome activation and NF-κB signaling.
- XFK upregulated miR-223 expression, and miR-223 overexpression mimicked XFK's protective effects, while miR-223 inhibition abrogated them, indicating a miR-223-dependent mechanism.
Conclusions:
- NF-κB-linked NLRP3 pyroptotic signaling is a key feature of the studied CHF model.
- XFK exerts cardioprotective effects in CHF by modulating NF-κB/NLRP3 pyroptotic signaling through a miR-223-dependent pathway.
- XFK shows potential as an adjunctive therapeutic strategy to mitigate inflammation-driven cardiac dysfunction in CHF.
Background:
Pyroptotic signaling involving nuclear factor-kappa B (NF-κB) and NOD-like receptor family pyrin domain-containing 3 (NLRP3) has been implicated in chronic heart failure (CHF). Xin-Fu-Kang (XFK) is a nine-herb formula used clinically for CHF with "qi deficiency and blood stasis." Although cardioprotective effects have been reported, it remains unclear whether XFK modulates myocardial pyroptotic signaling via miR-223-dependent regulation of NF-κB.
Methods:
A CHF model was established by permanent left anterior descending coronary artery (LADCA) ligation in rats, and an in vitro oxygen-glucose deprivation/reoxygenation (OGD/R) injury model was generated in H9c2 cardiomyocytes. Cardiac structure and function were assessed by transthoracic echocardiography and histology. Myocardial inflammation and pyroptotic signaling were quantified by ELISA for interleukin-1 beta (IL-1β) and interleukin-18 (IL-18), and by immunoblotting for NLRP3, pro-caspase-1/caspase-1 ratio, Apoptosis-associated speck-like protein containing a CARD (ASC), cleaved gasdermin D N-terminal fragment (GSDMD-N), and NF-κB p65 phosphorylation. Nuclear-cytoplasmic fractionation and immunofluorescence tracked p65 translocation. Causality was probed by miR-223 gain- and loss-of-function, with functional rescue using a miR-223 inhibitor. RT-qPCR was used to measure the mRNA levels of NF-κB p65 and miR-223.
Results:
LADCA produced marked systolic dysfunction with chamber dilation, increased myocardial IL-1β and IL-18, increased NLRP3, ASC, GSDMD-N, and p65 phosphorylation, and decreased the pro-caspase-1/caspase-1 ratio. XFK improved cardiac function and structural integrity, attenuated fibrosis and cardiomyocyte apoptosis, reduced inflammatory cytokines, and diminished NLRP3 and ASC abundance. In OGD/R-injured H9c2 cells, XFK preserved viability, limited lactate dehydrogenase release, decreased NLRP3, ASC, GSDMD-N, and IL-1β, increased the pro-caspase-1/caspase-1 ratio, and restrained NF-κB activation by reducing p65 phosphorylation and nuclear translocation. Mechanistically, XFK upregulated miR-223, and miR-223 overexpression reproduced the suppression of pyroptosis-related readouts linked to NF-κB/NLRP3 signaling. Inhibition of miR-223 attenuated the protective effects of XFK, supporting the interpretation that XFK-mediated modulation of NF-κB-related inflammatory signaling is at least partly dependent on miR-223.
Conclusion:
NF-κB-linked NLRP3 pyroptotic signaling represents a prominent feature in the CHF model examined. These findings suggest that XFK exerts protective effects in CHF via miR-223-dependent modulation of NF-κB/NLRP3 pyroptotic signaling, supporting its potential adjunctive strategy to mitigate inflammation-driven cardiac dysfunction.
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Diuretics